<?xml version="1.0" encoding="UTF-8"?>
<p>The recent Ebola and Zika epidemics highlighted how poorly prepared we were to deal with these new and emerging diseases. There has therefore been a global drive to develop vaccines against these diseases and improve preparedness. The Coalition for Epidemic Preparedness Innovation's (CEPI's) was established in 2016 with a mandate of financing and coordinating the development of new human vaccines to prevent and contain infectious disease epidemics. CEPI selected NiV, Lassa virus and Middle East respiratory syndrome-coronavirus, three pathogens from the WHO's list of priority diseases needing urgent R&amp;D attention as its initial focus (
 <xref rid="B50" ref-type="bibr">50</xref>, 
 <xref rid="B51" ref-type="bibr">51</xref>). The WHO's list of priority diseases is part of the R&amp;D Blueprint, which identifies priority diseases and addresses gaps in the global scientific community to increase preparedness for future outbreaks. The main aim of the Blueprint is to fast-track the availability of effective tests, vaccines, and medicines that can be used to save lives and avert large scale crises (
 <xref rid="B51" ref-type="bibr">51</xref>).
</p>
